New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.

Published

Journal Article (Review)

A small subset of T cells (gamma-delta T cells) is able to recognize phosphoantigens that are overexpressed in some cancer cells and may selectively target and kill cancer cells with high levels of phosphoantigen. Moreover, nitrogen-containing bisphosphonates, such as zoledronic acid, are able to induce accumulation of specific phosphoantigens in some cancer cells. A recent preclinical study showed that gamma-delta T cells effectively targeted and killed zoledronic acid-treated estrogen-receptor-positive breast cancer cells. These new data provide growing insight into a potential mechanism of action for some of the anticancer activity demonstrated by zoledronic acid in breast cancer clinical trials.

Full Text

Duke Authors

Cited Authors

  • Hamilton, E; Clay, TM; Blackwell, KL

Published Date

  • October 2011

Published In

Volume / Issue

  • 29 / 8

Start / End Page

  • 533 - 541

PubMed ID

  • 21843051

Pubmed Central ID

  • 21843051

Electronic International Standard Serial Number (EISSN)

  • 1532-4192

International Standard Serial Number (ISSN)

  • 0735-7907

Digital Object Identifier (DOI)

  • 10.3109/07357907.2011.605413

Language

  • eng